Moxonidine for arterial hypertension treatment in menopausal women with metabolic syndrome
Aim. To investigate clinical effectiveness of imidazoline receptor agonist, moxonidine, in arterial hypertension (AH) treatment among women with menopausal metabolic syndrome (MMS). Material and methods. In total, 38 women (mean age 51,4±0,3 years) with MMS received moxonidine (0,2-0,6 mg/d, accordi...
Saved in:
Main Authors: | V. V. Trusov, K. V. Aksenov, T. E. Chernyshova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«SILICEA-POLIGRAF» LLC
2007-08-01
|
Series: | Кардиоваскулярная терапия и профилактика |
Subjects: | |
Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1278 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Imidazoline receptor agonist moxonidine and arterial hypertension treatment in women with menopausal metabolic syndrome
by: E. V. Tishina, et al.
Published: (2011-06-01) -
Moxonidine-based combination antihypertensive therapy in patients with metabolic syndrome
by: E. V. Tishina, et al.
Published: (2012-06-01) -
Arterial hypertension in women with climacteric syndrome
by: V. I. Podzolkov, et al.
Published: (2005-10-01) -
ADDITIONAL BENEFITS OF ANTIHYPERTENSIVE MOXONIDINE THERAPY IN POSTMENOPAUSAL WOMEN WITH ARTERIAL HYPERTENSION
by: E. N. Dudinskaya, et al.
Published: (2014-02-01) -
Direct renin inhibitor aliskiren in women with menopausal metabolic syndrome and arterial hypertension
by: Yu. V. Zhernakova, et al.
Published: (2011-08-01)